Effect of Δ9-tetrahydrocannabinol on monoamine oxidase activity of rat tissues in vivo

Cannabinoids and monoamine neurotransmission with focus on monoamine oxidase

Progress in understanding the mechanisms of action of cannabinoids was made after discovery of cannabinoid receptors and finding their endogenous ligands. New findings are obtained using both endogenous cannabinoids and plant or synthetic cannabinoids. Activation of cannabinoid receptors on synaptic terminals results in regulation of ion channels, neurotransmitter release and synaptic plasticity. Neuromodulation of synapses by cannabinoids is proving to have a wide range of functional effects, making them potential targets as medical preparations in a variety of illnesses, including some neurodegenerative and mental disorders. Brain monoamines are involved in many of the same processes affected by neuropsychiatric disorders and by different psychotropic drugs, including cannabinoids. Basic information is summarized in the paper about mechanisms of action of cannabinoids on monoaminergic systems, with a view to inhibition of monoamine oxidase.

Inhibition of monoamine oxidase activity by cannabinoids

Brain monoamines are involved in many of the same processes affected by neuropsychiatric disorders and psychotropic drugs, including cannabinoids. This study investigated in vitro effects of cannabinoids on the activity of monoamine oxidase (MAO), the enzyme responsible for metabolism of monoamine neurotransmitters and affecting brain development and function. The effects of the phytocannabinoid Delta(9)-tetrahydrocannabinol (THC), the endocannabinoid anandamide (N-arachidonoylethanolamide [AEA]), and the synthetic cannabinoid receptor agonist WIN 55,212-2 (WIN) on the activity of MAO were measured in a crude mitochondrial fraction isolated from pig brain cortex. Monoamine oxidase activity was inhibited by the cannabinoids; however, higher half maximal inhibitory concentrations (IC(50)) of cannabinoids were required compared to the known MAO inhibitor iproniazid. The IC(50) was 24.7 micromol/l for THC, 751 micromol/l for AEA, and 17.9 micromol/l for WIN when serotonin was used as substrate (MAO-A), and 22.6 micromol/l for THC, 1,668 micromol/l for AEA, and 21.2 micromol/l for WIN when phenylethylamine was used as substrate (MAO-B). The inhibition of MAOs by THC was noncompetitive. N-Arachidonoylethanolamide was a competitive inhibitor of MAO-A and a noncompetitive inhibitor of MAO-B. WIN was a noncompetitive inhibitor of MAO-A and an uncompetitive inhibitor of MAO-B. Monoamine oxidase activity is affected by cannabinoids at relatively high drug concentrations, and this effect is inhibitory. Decrease of MAO activity may play a role in some effects of cannabinoids on serotonergic, noradrenergic, and dopaminergic neurotransmission.

delta 9-Tetrahydrocannabinol-induced changes in beta-adrenergic receptor binding in mouse cerebral cortex

The effects of 3 cannabinoids, delta 9-tetrahydrocannabinol (delta 9-THC), 11-OH-delta 9-tetrahydrocannabinol (11-OH-delta 9-THC) and cannabidiol (CBD) on the binding of [3H]dihydroalprenolol [( 3H]DHA) to mouse brain beta-adrenergic receptors were determined. In vitro, delta 9-THC and 11-OH-delta 9-THC increased the specific binding of [3H]DHA. The increased specific binding of [3H]DHA was due to an increase in receptor affinity as indicated by a decrease in the dissociation constant (Kd). CBD had no effect on binding. Chronic administration of delta 9-THC in vivo caused a decrease in the number of [3H]DHA binding sites with no change in Kd.

Environmental stress as a factor in the response of rat brain catecholamine metabolism to delta8-tetrahydrocannabinol

In rats housed normally (aggregated, food and water ad lib) for fourteen days delta8-tetrahydrocannabinol (THC) produced mild sedation and minimal hypothermia. An increase in noradrenaline synthesis was observed, but brain dopamine metabolism was unchanged. In rats removed from this 'normal' environment to conditions of isolation and food deprivation for 24 h THC produced immobility, marked hyper-reactivity, and hypothermia. Brain noradrenaline metabolism was unchanged by THC under these conditions, but significant changes in striatal dopamine metabolism were observed. These changes are consistent with increased dopamine reuptake in striatum produced by this combination of THC and novel environment. It is suggested that some of the behavioural effects of cannabis administered under stressful conditions may be related to alterations in striatal dopamine metabolism.